This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background Drug-eluting stents (DESs) have become the gold standard of coronary angioplasty since their inception in 2002. vs 57.5%, p=0.010), a greater average number of stents implanted per patient (1.72±0.92 To date, no study has shown the superiority of one type of polymer compared with the other.
In the DA+DCB arm, there was a trend toward higher stent-free patency through 12 months (79.1% versus 68.1%, · P=0.09) and a significantly lower provisional stenting rate (9.5% among 6 randomized controlled trials (RCTs) (172 patients), comparing favorably to published meta-analysis rates for uncoated balloon angioplasty (47.4%
All patients had headache, and funduscopic examination demonstrated papilledema for all patients. All patients had headache, and funduscopic examination demonstrated papilledema for all patients. All patients had headache, and funduscopic examination demonstrated papilledema for all patients.
The United States has been way behind other nations in using drug-coated balloons (DCB) to treat coronary in-stent restenosis (ISR), but that’s about to change thanks to the FDA approval of Boston Scientific’s AGENT Drug-Coated Balloon. vs 12.3%) Stentthrombosis (0.0% vs 12.3%) Stentthrombosis (0.0%
Overall, 27/36 procedures were interventional, including 6 aortic valvuloplasties, 6 balloon angioplasties, and 15 stenting procedures. Results We identified 30 patients (66.7% males) with a median age of 1.1 months (IQR, 0.3–5.4), 5.4), and a median weight of 3.1 kg kg (IQR, 2.7–3.7). months (IQR, 1.7–5.1). mm (IQR, 2.4–3).
Introduction:Subacute stentthrombosis (ST) is related to high rates of cardiac reinfarction. Two weeks prior he had impella guided LM bifurcation PCI with DES and ramus intermedius (RI) angioplasty (PTA) but was nonadherent to clopidogrel. Circulation, Volume 150, Issue Suppl_1 , Page A4137144-A4137144, November 12, 2024.
Repeat ECG while waiting for cath team, t = 56 min after arrival: It is getting worse Angiogram showed 99% acute proximal LAD thrombosis. It was opened and stented. The Cath lab was activated. Peak trop > 50,000 ng/L Formal Bubble contrast echo Severe LV systolic dysfunction.
The lesion was intervened on with balloon angioplasty and had subsequent TIMI 3 flow. It was thought to be an in stent restenosis and thrombosis from a DES placed in the same region 6 months prior. There was initially TIMI 0 flow. His troponin I peaked at 97 ng/mL (very large MI!).
Deep Vein Thrombosis (DVT) : A blood clot occurring in a deep vein. Causes include infection, malignancy, surgery, scar tissue formation, trauma, deep vein thrombosis (DVT), radiation or other cancer treatment. Angioplasty & Stenting: Opens blocked arteries to improve blood flow.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content